- Home
- INVA vs RCKT Comparison
INVA vs RCKT Comparison
Compare INVA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- RCKT
- Stock Information
- Founded
- INVA 1996
- RCKT 1999
- Country
- INVA United States
- RCKT United States
- Employees
- INVA N/A
- RCKT N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- RCKT Health Care
- Exchange
- INVA Nasdaq
- RCKT Nasdaq
- Market Cap
- INVA 1.3B
- RCKT 1.4B
- IPO Year
- INVA 2004
- RCKT N/A
- Fundamental
- Price
- INVA $18.90
- RCKT $13.98
- Analyst Decision
- INVA Buy
- RCKT Strong Buy
- Analyst Count
- INVA 1
- RCKT 9
- Target Price
- INVA N/A
- RCKT $53.22
- AVG Volume (30 Days)
- INVA 575.7K
- RCKT 744.0K
- Earning Date
- INVA 11-06-2024
- RCKT 11-07-2024
- Dividend Yield
- INVA N/A
- RCKT N/A
- EPS Growth
- INVA 46.55
- RCKT N/A
- EPS
- INVA 0.99
- RCKT N/A
- Revenue
- INVA $352,745,000.00
- RCKT N/A
- Revenue This Year
- INVA $14.10
- RCKT N/A
- Revenue Next Year
- INVA N/A
- RCKT $411.05
- P/E Ratio
- INVA $19.08
- RCKT N/A
- Revenue Growth
- INVA 21.46
- RCKT N/A
- 52 Week Low
- INVA $13.41
- RCKT $13.80
- 52 Week High
- INVA $21.28
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- INVA 35.97
- RCKT 27.71
- Support Level
- INVA $18.40
- RCKT $16.65
- Resistance Level
- INVA $21.28
- RCKT $17.83
- Average True Range (ATR)
- INVA 0.61
- RCKT 0.89
- MACD
- INVA -0.08
- RCKT -0.27
- Stochastic Oscillator
- INVA 17.36
- RCKT 4.12
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.